FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011663640> ?p ?o ?g. }

• W2011663640 endingPage "1896" @default.
• W2011663640 startingPage "1892" @default.
• W2011663640 abstract "No AccessJournal of UrologyClinical Urology: Original Article1 Jun 1996The Effect of Lubricants on Viability of Bacillus Calmette-Guerin for Intravesical Immunotherapy Against Bladder Carcinoma A. Bohle, S. Rusch-Gerdes, A.J. Ulmer, H. Braasch, and D. Jocham A. BohleA. Bohle More articles by this author , S. Rusch-GerdesS. Rusch-Gerdes More articles by this author , A.J. UlmerA.J. Ulmer More articles by this author , H. BraaschH. Braasch More articles by this author , and D. JochamD. Jocham More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66040-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The viability of bacillus Calmette-Guerin (BCG) is crucial for induction of a local immune response and for effective therapy of recurrent superficial bladder carcinoma. During intravesical instillation of BCG lubricants are administered to assist catheterization, which contain bacteriostatic components that may interfere with the viability of mycobacteria. To verify this assumption, 5 commercially available lubricants were analyzed with regard to inhibition of viable BCG growth. Materials and Methods: Five different lubricants and their components were co-incubated with Connaught strain BCG and the resultant growth of BCG was assessed. To prove the significant passage of lubricants into the bladder, fluid was recovered from the bladder after catheterization, analyzed with regard to the bacteriostatic effect and compared to normal urine of different acidity. Results: Significant impairment of BCG viability, dependent on dosage and time of co-incubation, was noted with all lubricants analyzed. Several components, namely lidocaine hydrochloride, glyceryl stearate, propyl-4-hydroxy-benzoate and chlorhexidine digluconate, were identified as responsible for this inhibition. Fluid recovered from the bladder after lubricant assisted catheterization also showed an inhibitory effect, indicating significant mixture of the instillate with lubricants. Conclusions: Generous use of lubricants to assist catheterization during intravesical BCG therapy will result in a clinically significant decrease in the number of intravesically instilled viable mycobacteria. For this reason, during intravesical immunotherapy with BCG only small amounts of lubricants should be used for urethral catheterization, and use of catheters not requiring lubricants should be considered. References 1 : The T1 bladder tumor. Sem. Urol.1990; 4: 254. Google Scholar 2 : Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J. Urol.1992; 147: 1020. Link, Google Scholar 3 : Intravesical BCG: current results, natural history, and implications for urothelial cancer prevention. J. Cell. Biochem.1992; 16I: 112. Google Scholar 4 : A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional-cell carcinoma of the bladder. New Engl. J. Med.1991; 325: 1205. Google Scholar 5 : Intravesical therapy: does it affect the natural history of superficial bladder cancer? Sem. Urol.1992; 10: 39. Google Scholar 6 : SWOG 8795: a randomized comparison of bacillus Calmette-Guerin and mitomycin C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. J. Urol.1993; 149: 282A. abstract 275. Google Scholar 7 : Fortschritte in der Behandlung des oberflachlichen Harnblasenkarzinoms mit BCG-Immuntherapie: Ergebnisse kontrollierter nordamerikanischer Studien. In: BCG-Therapie des oberflachlichen Harnblasenkarzinoms. Bestandsaufnahme aus Klinik und Praxis. Edited by . New York: Springer-Verlag1994: 12. Google Scholar 8 : Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J. Urol.1990; 144: 59. Abstract, Google Scholar 9 : Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol.1990; 144: 53. Link, Google Scholar 10 : HLA-DR expression by high grade superficial bladder cancer treated with BCG. Brit. J. Urol.1989; 63: 264. Google Scholar 11 : Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol.1992; 147: 1636. Link, Google Scholar 12 : Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J. Urol.1985; 134: 48. Link, Google Scholar 13 : Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with bacillus Calmette-Guerin. Cancer Res.1984; 44: 3051. Medline, Google Scholar 14 : Hispathology of tumor regression after intralesional injection of mycobacterum bovis. III. Development of immunity to tumor cells and BCG. J. Natl. Cancer Inst.1973; 51: 1897. Google Scholar 15 : Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guerin. J. Natl. Cancer Inst.1971; 46: 831. Google Scholar 16 : Suppression of murine tumor growth by immune reaction to the bacillus Calmette-Guerin strain of Mycobacterium bovis. J. Natl. Cancer Inst.1972; 48: 245. Google Scholar 17 : Requirement of a thymus-dependant immune response for BCG-mediated antitumor activity. J. Urol.1987; 137: 155. Abstract, Google Scholar 18 : The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol. Immunother.1995; 40: 103. Google Scholar 19 : Dissecting the immunobiological effects of bacillus Calmette-Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J. Urol.1993; 150: 1932. Link, Google Scholar 20 : Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional cells in patients with urinary bladder cancer. Cancer1992; 69: 537. Google Scholar 21 : Immunotherapy of guinea pig cancer with BCG. Cancer, suppl.1974; 34: 1532. Google Scholar 22 : Immunotherapy of murine transitional cell carcinoma. J. Urol.1982; 128: 1104. Link, Google Scholar 23 : Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement of the expression of an antitumor response. J. Clin. Invest.1990; 85: 62. Google Scholar 24 : Inhibition of murine bladder tumor growth by bacillus Calmette-Guerin: lack of a role of natural killer cells. Clin. Immunol. Immunopath.1986; 41: 108. Google Scholar 25 : Intravesical BCG therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res.1987; 47: 1762. Google Scholar 26 : Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res.1983; 43: 1611. Google Scholar 27 : The male urethra: capacity determination and its significance for urology. Urologe A1978; 17: 238. Google Scholar 28 : BCG immunotherapy of superficial bladder cancer: treatment results, risks, and complications. J. Cancer Res. Clin. Oncol.1990; 116: 541. Google Scholar 29 : Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol.1992; 147: 596. Link, Google Scholar 30 : Systemic complications of intravesical bacillus Calmette-Guerin therapy for bladder cancer. Letter to the Editor. Lancet1985; 19: 899. Google Scholar 31 : Complications of bacillus Calmette-Guerin immunotherapy. Urol. Clin. N. Amer.1992; 19: 565. Crossref, Medline, Google Scholar From the Department of Urology, Medical University of Lubeck, National Reference Centre of Mycobacteria and Department of Immunology and Cell Biology, Forschungsinstitut Borstel, Lubeck, Germany.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 155Issue 6June 1996Page: 1892-1896 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information A. Bohle More articles by this author S. Rusch-Gerdes More articles by this author A.J. Ulmer More articles by this author H. Braasch More articles by this author D. Jocham More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2011663640 created "2016-06-24" @default.
• W2011663640 creator A5002400084 @default.
• W2011663640 creator A5019943798 @default.
• W2011663640 creator A5063110744 @default.
• W2011663640 creator A5072287287 @default.
• W2011663640 creator A5082481600 @default.
• W2011663640 date "1996-06-01" @default.
• W2011663640 modified "2023-09-26" @default.
• W2011663640 title "The Effect of Lubricants on Viability of Bacillus Calmette-Guerin for Intravesical Immunotherapy Against Bladder Carcinoma" @default.
• W2011663640 cites W1423791052 @default.
• W2011663640 cites W162085154 @default.
• W2011663640 cites W162594705 @default.
• W2011663640 cites W1709508 @default.
• W2011663640 cites W1893346712 @default.
• W2011663640 cites W1994396826 @default.
• W2011663640 cites W2000828919 @default.
• W2011663640 cites W2036535589 @default.
• W2011663640 cites W2053811431 @default.
• W2011663640 cites W2054281103 @default.
• W2011663640 cites W2081166109 @default.
• W2011663640 cites W2091814508 @default.
• W2011663640 cites W2137937400 @default.
• W2011663640 cites W229763590 @default.
• W2011663640 cites W2333193688 @default.
• W2011663640 cites W2408301264 @default.
• W2011663640 cites W2414572565 @default.
• W2011663640 cites W2422389937 @default.
• W2011663640 cites W2429123395 @default.
• W2011663640 cites W2460892140 @default.
• W2011663640 doi "https://doi.org/10.1016/s0022-5347(01)66040-3" @default.
• W2011663640 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8618281" @default.
• W2011663640 hasPublicationYear "1996" @default.
• W2011663640 type Work @default.
• W2011663640 sameAs 2011663640 @default.
• W2011663640 citedByCount "10" @default.
• W2011663640 countsByYear W20116636402017 @default.
• W2011663640 crossrefType "journal-article" @default.
• W2011663640 hasAuthorship W2011663640A5002400084 @default.
• W2011663640 hasAuthorship W2011663640A5019943798 @default.
• W2011663640 hasAuthorship W2011663640A5063110744 @default.
• W2011663640 hasAuthorship W2011663640A5072287287 @default.
• W2011663640 hasAuthorship W2011663640A5082481600 @default.
• W2011663640 hasConcept C126322002 @default.
• W2011663640 hasConcept C126894567 @default.
• W2011663640 hasConcept C203014093 @default.
• W2011663640 hasConcept C2777546739 @default.
• W2011663640 hasConcept C2777701055 @default.
• W2011663640 hasConcept C2779150676 @default.
• W2011663640 hasConcept C2779762690 @default.
• W2011663640 hasConcept C502942594 @default.
• W2011663640 hasConcept C71924100 @default.
• W2011663640 hasConcept C86803240 @default.
• W2011663640 hasConcept C8891405 @default.
• W2011663640 hasConcept C89423630 @default.
• W2011663640 hasConceptScore W2011663640C126322002 @default.
• W2011663640 hasConceptScore W2011663640C126894567 @default.
• W2011663640 hasConceptScore W2011663640C203014093 @default.
• W2011663640 hasConceptScore W2011663640C2777546739 @default.
• W2011663640 hasConceptScore W2011663640C2777701055 @default.
• W2011663640 hasConceptScore W2011663640C2779150676 @default.
• W2011663640 hasConceptScore W2011663640C2779762690 @default.
• W2011663640 hasConceptScore W2011663640C502942594 @default.
• W2011663640 hasConceptScore W2011663640C71924100 @default.
• W2011663640 hasConceptScore W2011663640C86803240 @default.
• W2011663640 hasConceptScore W2011663640C8891405 @default.
• W2011663640 hasConceptScore W2011663640C89423630 @default.
• W2011663640 hasIssue "6" @default.
• W2011663640 hasLocation W20116636401 @default.
• W2011663640 hasLocation W20116636402 @default.
• W2011663640 hasOpenAccess W2011663640 @default.
• W2011663640 hasPrimaryLocation W20116636401 @default.
• W2011663640 hasRelatedWork W1523028220 @default.
• W2011663640 hasRelatedWork W2085899929 @default.
• W2011663640 hasRelatedWork W2127901112 @default.
• W2011663640 hasRelatedWork W2167489672 @default.
• W2011663640 hasRelatedWork W2303819910 @default.
• W2011663640 hasRelatedWork W2369087181 @default.
• W2011663640 hasRelatedWork W2410576223 @default.
• W2011663640 hasRelatedWork W2606730670 @default.
• W2011663640 hasRelatedWork W2742475499 @default.
• W2011663640 hasRelatedWork W4255528288 @default.
• W2011663640 hasVolume "155" @default.
• W2011663640 isParatext "false" @default.
• W2011663640 isRetracted "false" @default.
• W2011663640 magId "2011663640" @default.
• W2011663640 workType "article" @default.